Berberine and Itraconazole Are not Synergistic in Vitro against Aspergillus fumigatus Isolated from Clinical Patients

Gao Lei 1, He Dan 1, Liu Jinhua 2, Yan Wei 1, Gao Song 1 and Wang Li 1,*

1 Department of Pathogenobiology, Norman Bethune College of Medicine, Jilin University, Jilin University Mycology Research Center (JUMRC), No.126 Xinmin Street, Changchun City, Jilin Province 130021, China

2 Technical Center of Jilin Entry-Exit Inspection and Quarantine Bureau (JLCIQ) of China, Changchun City, Jilin Province 130062, China

* Author to whom correspondence should be addressed; E-Mail: wli99@jlu.edu.cn; Tel.: +86-431-8561-9486.

Received: 15 October 2011; in revised form: 29 October 2011 / Accepted: 31 October 2011 / Published: 3 November 2011

Abstract: The incidence of Aspergillus fumigatus infections has become more frequent as a consequence of widespread immunosuppression. At present, the number of available antifungal agents in the clinic is limited, and most of them, such as itraconazole (ICZ), are toxic and show resistance. Berberine (BER) is a plant alkaloid used in the clinic mainly for alimentary infections. We have used BER and ICZ to measure in vitro resistance in A. fumigatus isolated from clinical patients. The minimum inhibitory concentration ranges of BER and ICZ were 4–256 and 0.031–0.250 μg/mL, respectively. In addition, against A. fumigatus IFM 40808 strain, the MIC50 values of BER and ICZ were 8 and 0.125 μg/mL. Using this strain, we compared the giant colonies with or without BER, and concluded that BER could restrain A. fumigatus mycelial growth and conidial pigment production. Combinations of the two drugs were also tested by the checkerboard assay to identify any functional interactions between them. Thirty-two out of 42 isolates had FICI values > 4.0, indicating that two drugs were mutually antagonistic. In conclusion, it is not advised that BER and ICZ be used in the clinic at the same time. Our results indicated that BER may inhibit A. fumigatus through the ergosterol biosynthesis pathway, like ICZ.

Keywords: Aspergillus fumigatus; berberine; itraconazole; ergosterol biosynthesis pathway
1. Introduction

Aspergillus fumigatus is an environmentally ubiquitous, spore-forming mold saprophyte. This airborne filamentous fungal pathogen is known to be a major cause of lethal lung infections in immunocompromised hosts and allergic asthma in atopic individuals [1]. Fungal infections including candidiasis, aspergillosis, cryptococcosis, and pneumocystosis often require hospitalization, with aspergillosis being the second most common cause [2]. Aspergillosis has high mortality rates, and its incidence has been increasing gradually [3]. Notwithstanding the increasing need for effective therapy, the range of antifungal agents available is limited, and some of the most effective agents are also toxic [4]. Treatment of A. fumigatus infections mainly involves azole derivatives, a class that includes itraconazole (C₃₅H₃₈Cl₂N₈O₄, Figure 1), which has historically been the front-line drug in these treatments [5]. However, the pharmacological profile of azole drugs is determined and restricted by their liver toxicity, metabolic elimination, and pharmacokinetic drug-drug interactions involving CYP3A4 metabolic inhibition [6].

Figure 1. Structure of itraconazole.

Berberine ([C₂₀H₁₇ClNO₅]⁺, Figure 2) is an isoquinoline plant alkaloid with a bright yellow color that is usually found in the stem bark, rhizomes and roots of the herb Berberis [7]. The alkaloid has multiple therapeutic actions and the use of berberine has been described for almost all disorders of the body. These plants are used medicinally in all traditional medical systems, and have a history of usage in Chinese and Korean medicine dating back at least 3,000 years. Berberine extract as a crude drug has been demonstrated to have significant antimicrobial activity against bacteria, viruses, protozoans, fungi, yeast [7,8], chlamydia and helminths (worms) [9]. The drug has been used in Chinese and Indian medicines for the treatment of bacterial diarrhea, intestinal parasitic infections, and ocular trachoma infections [10].

Figure 2. Structure of berberine.
Testing of the effects of crude drugs on isolated fungi has been performed in China for over a thousand years as a means of identifying putative efficacious preparations. According to previous reports, berberine has both antifungal [4,11-14] and antibacterial effects [15-18] under in vitro conditions. We show here that berberine has antifungal effects on the growth of \textit{A. fumigatus}, as determined by the minimum inhibitory concentration (MIC) method. We have also investigated whether berberine has a synergic effect with itraconazole \textit{in vitro} when tested against \textit{A. fumigatus} and whether the alkaloid berberine is a valid therapeutic agent against \textit{A. fumigatus}. We have reached the conclusion that berberine and itraconazole inhibit \textit{A. fumigatus} by similar mechanisms of action and are not synergistic.

2. Results and Discussion

2.1. Results

2.1.1. Influence of BER and ICZ on \textit{A. fumigatus}

The median MIC\textsubscript{50} values of BER and ICZ for \textit{A. fumigates} were individually calculated. The MIC range of BER over the 42 strains used was 4–256 \(\mu\text{g/mL}\). The MIC range of ICZ (Table 1) was 0.031–0.250 \(\mu\text{g/mL}\) (42 strains). In addition, in \textit{A. fumigatus} IFM 40808 cultures, the MIC\textsubscript{50} of BER and ICZ was 8 and 0.125 \(\mu\text{g/mL}\).

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|}
\hline
\textbf{Strain No.} & \textbf{MIC\textsubscript{50} (\(\mu\text{g/mL}\))} & & \\
& BER & ICZ & FICI \\
\hline
IFM 40808 & 8 & 0.125 & 4.5 \\
JLCC 30436 & 256 & 0.250 & 3.7 \\
JLCC 30468 & 8 & 0.031 & 5.5 \\
JLCC 30470 & 8 & 0.031 & 8.0 \\
JLCC 30482 & 32 & 0.063 & 3.5 \\
JLCC 30490 & 8 & 0.031 & 4.2 \\
JLCC 30506 & 32 & 0.063 & 4.7 \\
JLCC 30507 & 32 & 0.063 & 3.9 \\
JLCC 30540 & 8 & 0.031 & 6.8 \\
JLCC 30541 & 4 & 0.031 & 7.0 \\
JLCC 30542 & 4 & 0.063 & 5.0 \\
JLCC 30545 & 128 & 0.125 & 2.9 \\
JLCC 30653 & 16 & 0.063 & 5.5 \\
JLCC 30654 & 8 & 0.063 & 2.5 \\
\hline
\end{tabular}
\caption{Action of BER and ICZ alone (MIC\textsubscript{50}, \(\mu\text{g/mL}\)) or in combination (FICI value) against \textit{A. fumigatus} isolates from clinical patients. Drug interactions were tested using the checkerboard microdilution method at a final inoculum of 0.5–2.5 \(\times 10^3\) CFU/mL, using RPMI 1640 medium buffered with 0.165 M MOPS. Final drug concentrations ranged from 0.036–0.5 \(\mu\text{g/mL}\) for ICZ and 1–128 \(\mu\text{g/mL}\) for BER. Plates were incubated at 35 °C for 48 h prior to analysis. The fractional inhibitory concentration index (FICI) is the sum of the MIC of each drug in combination divided by the MIC of the drug used alone. A FICI value $\leq 0.5$ is ‘synergy’; FICI $> 4.0$ is ‘antagonism’ and FICI $> 0.5$ and $\leq 4.0$ is ‘no interaction’.}
\end{table}
Table 1. Cont.

| Strain No. | MIC<sub>50</sub> (μg/mL) | FICI |
|------------|-------------------------|------|
|            | BER | ICZ |            |
| JLCC 30685 | 128 | 0.125 | 7.5 |
| JLCC 30717 | 8 | 0.031 | 6.9 |
| JLCC 30753 | 8 | 0.031 | 5.5 |
| JLCC 30782 | 4 | 0.031 | 8.0 |
| JLCC 30796 | 16 | 0.063 | 4.8 |
| JLCC 30854 | 8 | 0.031 | 3.0 |
| JLCC 30858 | 256 | 0.250 | 4.1 |
| JLCC 30859 | 256 | 0.250 | 3.5 |
| JLCC 30860 | 4 | 0.031 | 5.0 |
| JLCC 30883 | 128 | 0.125 | 4.6 |
| JLCC 30890 | 8 | 0.031 | 6.5 |
| JLCC 31354 | 8 | 0.031 | 5.0 |
| JLCC 31473 | 8 | 0.031 | 8.0 |
| JLCC 31495 | 4 | 0.031 | 8.0 |
| JLCC 31631 | 8 | 0.031 | 5.7 |
| JLCC 31584 | 8 | 0.031 | 8.0 |
| JLCC 31658 | 8 | 0.031 | 7.0 |
| JLCC 31660 | 4 | 0.031 | 6.0 |
| JLCC 31661 | 8 | 0.031 | 5.1 |
| JLCC 31671 | 8 | 0.031 | 4.4 |
| JLCC 31683 | 8 | 0.031 | 4.5 |
| JLCC 31699 | 32 | 0.125 | 4.0 |
| JLCC 31715 | 8 | 0.031 | 4.9 |
| JLCC 32069 | 16 | 0.063 | 4.4 |
| JLCC 32071 | 256 | 0.250 | 3.7 |
| JLCC 32712 | 8 | 0.031 | 3.9 |
| JLCC 33802 | 8 | 0.031 | 6.6 |
| JLCC 33803 | 4 | 0.031 | 8.0 |

After 5 days the bioassays showed that with increasing concentrations of BER, the growth of *A. fumigatus* could be significantly inhibited. When the concentration was more than 256 μg/mL, there was no colonies visible on plates (see Figure 3), and therefore we concluded that the MIC<sub>50</sub> was 256 μg/mL on the agar plates.

We compared the giant colonies of *A. fumigatus* treated with DMSO alone and treated with BER (at the 1/2 MIC<sub>50</sub> values of 128 μg/mL) to investigate the effect of BER on colony size (Table 2), mycelial growth and conidial pigment at 3, 5, 7 and 10 day. Colonies changed from granular to cottony, velvety, or powdery. At 3 day, the colonies were green, darkening to blue-green at 5 day, with a white apron at the colony margin. *A. fumigatus* on PDA at 7 days had a typical green-gray surface pigment with a suede-like surface texture consisting of a dense felt of conidiophores. *A. fumigatus* treated with BER exhibited smaller colony size, slower mycelial growth, and reduced conidia. These cultures also lost conidial pigment such that the conidial surface observed was white rather than green-gray (Figure 4). Figure 5 shows the results of morphological analysis of *A. fumigatus* in slide culture, with notable changes occurring in various morphological features (Figures 5B–H). These results demonstrate that BER can restrain *A. fumigatus* growth, development and conidial pigmentation.
**Figure 3.** *A. fumigatus* spores were spotted onto the centre of PDA plates containing different concentrations of BER (512, 256, 128, 64, 32, 16, 8 and 4 μg/mL), and control (+) was treated with DMSO only (the final concentrations of DMSO less than 1%), control (−) was only a PDA without fungus. All plates were incubated at 35 °C. After 7 days, bioassays showed, with increasing concentrations of BER, it could significantly inhibit the growth of *A. fumigates*. The MIC was taken as the lowest concentration of the drug that showed not any fungal colonies growth on the agar plates. When the concentration was more than 256 μg/mL, there were no colonies visible on plates.

**Table 2.** The colony sizes of *A. fumigatus* alone or *A. fumigatus* treated with BER (at 128 μg/mL).

| Giant colonies          | Diameter (cm) |
|------------------------|---------------|
|                        | 3 d           | 5 d           | 7 d           | 10 d          |
| *A. fumigatus* alone   | 1.19 ± 0.09   | 4.29 ± 0.11   | 6.99 ± 0.13   | 9.00 ± 0.10   |
| *A. fumigatus* treated with BER | 0.04 ± 0.07   | 1.50 ± 0.08   | 3.92 ± 0.09   | 7.10 ± 0.09   |

**Figure 4.** *A. fumigatus* without (left) and with (right) treatment with BER (at the 1/2 MIC$_{50}$ 128 μg/mL), comparing giant colonies grown on PDA at 35 °C for 3 days (A), 5 days (B), 7 days (C) or 10 days (D). Effects of BER on colony size, mycelial growth and conidial pigment were investigated. Images shown are representative of three independent experiments.
Figure 5. Lactophenol cotton blue preparation of a slide culture of *A. fumigatus* (original × 200). Images of intact structures of normal and mutation (treated with BER at 1/2 MIC<sub>50</sub> on plates) strains of *A. fumigatus* using an Axiovert 200 MAT microscope (Zeiss, Germany) by slide culture techniques at 3 day (A). Microscopic view of *A. fumigatus* showing typical columnar, uniseriate conidial heads. *A. fumigatus* grows at 45 °C. Note the conical-shaped terminal vesicles supporting a single row of phialides on the upper two-thirds of the vesicle. Vesicles are uniseriate and are covered by phialides / conidia on only the distal half. Conidia arise in chains and tend to sweep toward the central axis (B, C, G). Strains treated with BER (at the 1/2 MIC<sub>50</sub>) showing the appearance of a septum in the conidiophores (B, D, G), elongation (G, H), and distortion of conidial heads and obscuration of metulae and phialides (B, C, G). Some mycelia were wreathed and some phialides arose circumferentially and were biseriate or uniseriate, with circumferential conidia obscuring vesicles (E, F).

2.1.2. Fractional Inhibitory Concentration Index

Calculation of FICI values for drug combinations is a useful indicator of the nature of functional drug interactions. FICI values between 0.5 and 4.0 indicate no interaction, whereas values below 0.5 and above 4.0 signify synergistic and antagonistic interactions, respectively. Table 1 shows FICI
values for the BER-ICZ combination in each of the 42 *A. fumigatus* strains used in this study. All calculated values were above 0.5, demonstrating that the drug interaction was not synergistic in any strain. Furthermore, 32 of the 42 strains gave a FICI value greater than 4.0, suggesting that the interaction between BER and ICZ in these strains was mutually antagonistic (*i.e.*, acting via identical pathways).

2.1.3. Assessment of Ergosterol Content

The results indicated that the fungal dry weight was 254.40 ± 0.12 mg for the control group, 150.60 ± 0.14 mg for the BER group, and 97.49 ± 0.13 mg for the ICZ group. The HPLC results suggested that the retention time of ergosterol was about 10 min whatever the extraction process used and the chromatograms in this zone were very similar (Figure 6). The standard curve was linear over the range of ergosterol concentrations from 0.0001 to 0.01 μg/mL, \( r^2 = 0.99983 \) with a slope of 25,924.25 and passing through the origin. The assay showed the variation coefficient less than 10%. The lower limit of the detector was established at detection 0.0001 μg/mL. Under our experimental conditions, ergosterol content in the control group was 0.067 mg/mL, in the BER group it was 0.025 mg/mL, and in the ICZ group it was 0.018 mg/mL. The results show ergosterol contents of BER and ICZ group were decreased (*P* < 0.01).

**Figure 6.** HPLC analysis of ergosterol in *A. fumigates*. Red was Control, green was BER, blue was ICZ.

2.1.4. Real-Time PCR

Many genes encoding proteins in the ergosterol biosynthesis pathway show differential expression levels following exposure to BER and ICZ. Seventeen representative target genes and a control gene
Molecules 2011, 16

Figure 7. Comparison of the changes in expression of ergosterol biosynthesis pathway gene, determined by real-time PCR approaches. Student’s t-test was used to determine whether fold changes in gene expression induced by BER or induced by ICZ were different from untreated control. Significant differences are denoted with ▲ (P_{BER} < 0.05), ★ (P_{ICZ} < 0.05) and ▲▲ (P_{BER} < 0.01), ★★ (P_{ICZ} < 0.01). The fold expression in A. fumigatus treated with BER or ICZ as compared with that in untreated control. The calibrator was non-treatment, for which the fold expression was 1.0.

2.2. Discussion

BER is an alkaloid isolated from Chinese and Korean medicinal plants that notably inhibits the growth of a wide range of Candida species [19-21]. BER is clinically used in diseases such as urinary tract infections and conjunctivitis caused by bacteria like Escherichia coli, Staphylococcus aureus and Shigella dysenteriae. In recent years, research has shown that BER can also be used to treat fungal and viral infections and other diseases such as diabetes, hypertension, hyperlipidemia and arrhythmia [22-28]. Recently, investigators have used BER combined with amphotericin B to treat disseminated candidiasis in a mouse model, and others have investigated synergistic interactions of BER with fluconazole against fluconazole-resistant clinical isolates of Candida albicans [4, 22, 29, 30].
Up to now, there has been no research on BER inhibition of *A. fumigatus*, or on the potential benefits of the combined effects of BER and ICZ. Our current study is the first to apply BER to clinically isolated *A. fumigatus* strains, and the first to use BER and ICZ in a combination treatment. Our results show that BER can inhibit the production of conidial pigment in *A. fumigatus* and consequently cause aberrations in *A. fumigatus* morphology and a reduction in its sporulation rate.

It is well known that drugs respond very differently in different background media. So we gave details as to how the MIC was obtained for BER on potato dextrose agar. We also show that BER and ICZ are mutually antagonistic in terms of their ability to inhibit *A. fumigatus* isolated from clinical patients. Furthermore, we have investigated the biomechanisms by which BER and ICZ inhibit the *A. fumigatus* ergosterol biosynthesis pathway. Ergosterol, one of the most basic components in fungal membranes, is involved in a multitude of biological functions, for instance, membrane fluidity regulation, distribution and activity of integral proteins and control of the cell cycle [31]. Indeed, controlling ergosterol and its biosynthetic pathway can impact fungal growth. Knowledge of the effects on the ergosterol biosynthesis in *A. fumigatus* has been key in the development of many antifungal drugs in clinical use and can hopefully aid the design of novel drugs [32]. Previous studies have shown that the majority of triazole drugs such as ICZ inhibit *A. fumigatus* isolates by targeting the ergosterol biosynthesis pathway [33]. In the present experiments, we found BER can inhibit ergosterol like ICZ. The results from our gene expression experiments also indicate that BER significantly inhibits gene expression in the *A. fumigatus* ergosterol biosynthesis pathway and that BER is significantly more effective than ICZ at inhibiting expression of the *Erg5, Cyp51A, Cyp51B* and *IMP* genes, which are related to pigment production in *A. fumigatus* conidia. It could be that inhibition of these genes causes albino characteristics in *A. fumigatus* conidia. The *IMP* gene is closely related to cell wall biosynthesis [34] and, by inhibiting its expression, BER may thus inhibit biosynthesis of fungal cell walls and cause growth and developmental aberrations in *A. fumigates* [35].

3. Experimental Section

3.1. Strains, Media and Conditions

*A. fumigatus* strain IFM 40808 was isolated from the lung of a 54-year-old female Japanese patient with invasive aspergillosis, and provided from the Medical Mycology Research Center, Chiba University, Japan. The other *A. fumigatus* strains used in this study (41 strains: JLCC 30436, JLCC 30468, JLCC 30470, JLCC 30482, JLCC 30490, JLCC 30506, JLCC 30507, JLCC 30507, JLCC 30540, JLCC 30541, JLCC 30542, JLCC 30545, JLCC 30653, JLCC 30654, JLCC 30685, JLCC 30717, JLCC 30753, JLCC 30782, JLCC 30796, JLCC 30854, JLCC 30858, JLCC 30859, JLCC 30860, JLCC 30883, JLCC 30890, JLCC 31354, JLCC 31473, JLCC 31495, JLCC 31631, JLCC 31584, JLCC 31658, JLCC 31660, JLCC 31661, JLCC 31671, JLCC 31683, JLCC 31699, JLCC 31715, JLCC 32069, JLCC 32071, JLCC 32712, JLCC 33802, JLCC 33803) were isolated from 244 randomly selected clinical fungal infection patients at the Hospital of Jilin University between January 2008 and December 2010. Each strain was identified according to its physiological and morphological characteristics, and identified by molecular biology (mitochondrial cytochrome *b* gene, mt *cyt b*) [36].
All strains were preserved in the Culture Collection of Jilin University Mycology Research Center (JLCC), China. Strains were cultured on potato dextrose agar medium (PDA; Becton Dickinson Co., Sparks, MD, USA) in C-shaped streaks at 35 °C for 3–4 days. Conidial suspensions were maintained in 0.9% NaCl-Tween 80 (0.01%) in sterile water at room temperature.

3.2. Antifungal Drug Susceptibility Testing

The minimum inhibitory concentration (MIC) of itraconazole (ICZ) (Sigma, Sigma-Aldrich Co., Louis, MO, USA) and berberine (BER) (Aldrich, Sigma-Aldrich Co., Louis, MO, USA) were tested following the Clinical and Laboratory Standards Institute document M38-A2 [37], with end points measured at 48 h (All drugs dissolved in dimethylsulfoxide (DMSO) (Sigma) and an initial ICZ concentration of 1,600 μg/mL, an initial BER concentration of 20,480 μg/mL). ICZ and BER were used over concentration ranges of 0.03–16 μg/mL and 1–512 μg/mL. A. fumigatus spores were harvested from the stock cultures and their concentration adjusted to 1.0 × 10⁶ colony-forming units (CFU)/mL by 0.9% NaCl-Tween80 sterile water. Then spores were spotted onto the centre of PDA plates containing different concentrations of BER (512, 256, 128, 64, 32, 16, 8 and 4 μg/mL, BER was dissolved in DMSO), and control group drug was used DMSO only (the final concentrations of DMSO less than 1%). The plates were incubated at 35 °C, and growth of filamentous fungi on plates was monitored after 7 days. The MIC₅₀ was taken as the lowest concentration of the drug that showed not any fungal colonies growth on the agar plates [38].

3.3. Strain Culture

Giant colonies of A. fumigatus IFM 40808 treated without and with BER (at the 1/2 MIC₅₀ of plate) were compared for size of colony, mycelial growth and conidial pigment at 3, 5, 7, 10 day. We also examined the intact structures of normal and BER strains at 3 day using an Axiovert 200 MAT microscope (Zeiss, Freiberg, Germany) using slide culture techniques described previously [39].

3.4. Fractional Inhibitory Concentration Index

Drug interactions were tested using the checkerboard microdilution method [40]. The checkerboard tests were performed by a broth microdilution reference procedure at a final inoculum of 1.0 × 10⁶–5.0 × 10⁶ CFU/mL, using RPMI 1640 medium (Roswell Park Memorial Institute, Sigma, Sigma-Aldrich Co., Louis, MO, USA) buffered with 0.165 M MOPS (3-(N-morpholino)propanesulfonic acid). Final concentrations ranged from 0.036 to 0.5 μg/mL for ICZ, and 1 to 128 μg/mL for BER. Ninety-six shadow masks were incubated at 35 °C for 48 h prior to analysis. The fractional inhibitory concentration index (FICI) is the sum of the MIC of each drug in combination divided by the MIC of the drug used alone. A FICI value ≤0.5 is classed as ‘synergy’, whereas a FICI value >4.0 denotes ‘antagonism’. Values >0.5 but ≤4.0 indicate that there is ‘no interaction’ between the drugs [41].
3.5. Assessment of Ergosterol Content

3.5.1. Total Ergosterol Extraction

The well-developed *A. fumigatus* sample was cultured on a slant which was rinsed with 10 mL sterile water (0.9% NaCl-Tween80). Conidial suspension (10^6 CFU/mL) was mixed with RPMI 1640 medium at 1:10. The media joined the MIC_{50} of BER and ICZ respectively (All drugs were dissolved in DMSO), and compared with control group (receiving DMSO only). The fungi were incubated at 35 °C, at 110 rpm shaking. *A. fumigatus* were grown separately in 150 mL flasks containing adequate medium. After 3 days, mycelia were collected by filtration and washed with sterile phosphate-buffered saline (PBS, pH = 7.4), and then freeze-dried (LABCONCO FreeZone Triad Freeze Dry Systems, Kansas City, MO, USA) and weighted (fungal dry weight).

To a weight of dried mycelia (50 mg) was added 25% alcoholic KOH (potassium hydroxide solution) (3:2 methanol-ethanol, 25 mL) and then the mixture was homogenised by vortexing for 2 min. The mixed culture was incubated in a 90 °C water bath for 2.5 h. After cooling to room temperature, the saponified mixture was extracted in a fume hood with ether (20 mL), and vigorously vortexed for 15 min at room temperature. After 2.5 h the upper ether layer was transferred to a clean glass tube and evaporated with a centrifugal evaporator (EYELA, CVE-2000, Tokyo, Japan) at 20 °C. These dry residues were re-dissolved again in 1 mL of methanol and used for high performance liquid chromatography (HPLC) analysis.

Ergosterol standard (purity > 98%) was purchased from Sigma (Fluka, Buchs, Switzerland). A standard curve consisting of 0.0001, 0.0005, 0.001, 0.002, 0.005, 0.01 mg/mL. All stock solutions (the samples and standards) were filtered through 0.45-m-pore-size polytetrafluoroethylene membranes (Acrodisc, Waters, Waltham, MA, USA) [42].

3.5.2. HPLC Analysis

Ergosterol contents were analyzed using an Agilent 1200 Series Rapid Resolution LC System (G1316A, Agilent Technologies, Santa Clara, CA, USA) including a -ZORBAX Extend C18 column (250 mm × 4.6 mm, 5 μm). Eluent: methanol/water (97/3) (100% HPLC grade). Flow Rate: 1 mL/min. Temperature: 25 ± 2 °C. Detection: UV (ultraviolet) at 282 nm. Each experiment were run triplicate and repeated at least three times.

3.6. Real-Time PCR

Using *A. fumigatus* IFM 40808, we compared the ergosterol biosynthesis pathway of *A. fumigatus* treated with either BER or ICZ (each at the MIC_{50} i.e., the MIC at which 50% of isolates are inhibited). Conidial suspensions were maintained at 1.0 × 10^6 CFU/mL and inoculated in RPMI 1640 medium with DMSO, 1640 medium with BER (at the MIC_{50}), 1640 medium with ICZ (at the MIC_{50}). Cultures were incubated aerobically at 35 °C/110 rpm for 96 h, and examined daily before being collected and freeze-dried. Total RNA (messenger RNA) was prepared using the Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA) and VERSA Mini Nucleic Acid Extraction Workstation (Aurora Biomed, Vancouver, BC, Canada). The RNA was then reverse transcribed using the Quantitect Reverse
Transcription Kit (Qiagen). The resultant cDNAs (complementary DNA) were subsequently analyzed by quantitative PCR (polymerase chain reaction) using a SYBR green master mix in an ABI 7500 thermocycler (Applied Biosystems, Foster City, CA, USA) following the manufacturer's recommended protocols. Table 3 shows the primers used in the real-time PCR experiments. Amplifications were performed with the following parameters: an initial preheat at 95 °C for 10 s, followed by 45 cycles at 95 °C for 5 s, 60 °C for 32 s, to detect and quantify the fluorescence at a temperature above the denaturation of primer-dimers. Once amplifications were completed, melting curves were obtained to identify PCR products. For each sample, PCR amplifications to quantify the expression of the constitutively-expressed GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) gene were performed as a reference using the primer pair F-GAPDH-F + F-GAPDH-R (Table 3) [43]. The experiment was repeated five times. The expression of each tested gene in the BER-treated or ICZ-treated sample relative to that of untreated sample was calculated using the $2^{-\Delta\Delta CT}$ method [44-46].

**Table 3.** Primers used in real-time PCR analysis.

| Locus tag       | Protein description | Primer sequence (5′-3′) | Size of PCR product (bp) |
|-----------------|---------------------|-------------------------|-------------------------|
| AFUA_1G04720(Erg1) | C-8 sterol isomerase | F: TGCGATGGTCGACTTATTGT  
R: ACCCATAGCACCACCCGGACATT | 105          |
| AFUA_5G07780(Erg1) | Squalenemonooxygenase Erg1 | F: ATTGACAGAGACCGAATGAC  
R: GCTGCTTCATGACTCGTTTG | 112          |
| AFUA_6G05140(Erg3) | Sterol delta 5,6-desaturase | F: AAGCCGTTTTGTGACGAACCC  
R: AAGAACGCTAGGAACCTG | 113          |
| AFUA_1G03950(Erg5) | Cytochrome P450 sterol C-22 desaturase | F: TCAATTCGCAGCTTACCCGA  
R: ATTCAGCAGGCTTCTTTTGG | 101          |
| AFUA_4G03630(Erg6) | Sterol 24-c-methyltransferase | F: CCGATCGTTCAAGACACATGAC  
R: TTTCATAGCTCCAGAGACCG | 107          |
| AFUA_4G06890(Erg11) | 14-alpha sterol demethylase Cyp51A | F: TGGCGACATGAGTAGATAACCC  
R: TCAGGACTTTTGCTGTCGAG | 101          |
| AFUA_7G03740(Erg11) | 14-alpha sterol demethylase Cyp51B | F: AAAATTCACCAGTCGTTCAG  
R: TTTCCTTGAAGACGGACGC | 100          |
| AFUA_1G03150(Erg24) | C-14sterol reductase | F: CGATTTGCTTACATGTCGTC  
R: TATGGGCTCTTCGTCGATGTC | 102          |
| AFUA_4G04820(Erg25) | C-4 methyl sterol oxidase Erg25 | F: GCCGAATATGCACTGACCTATT  
R: TCGTGAAATAGATGCGAGCTTGC | 102          |
| AFUA_8G02440(Erg25) | C-4 methyl sterol oxidase | F: AGGGCGATTGTTCCGCCATC  
R: RGAACCGTCACCACATCAGCACA | 115          |
| AFUA_2G15030(Erg26) | C-3 sterol dehydrogenase/C-4 decarboxylase | F: AAGGATCCGGGGCGAGCCCAAG  
R: AAGAAGACGGTATGCGCGCAAG | 112          |
| AFUA_2G17400(Erg26) | C-3 sterol dehydrogenase/C-4 decarboxylase family protein | F: GTGAGATTGGCAACAAACAGAA  
R: ATTTTGCGCATGAAACACCAAC | 102          |
| AFUA_4G11500(Erg27) | 3-keto steroid reductase | F: ACGAGGTACCTTTTGTGGCTGA  
R: CACGATCGCATCGAGTTTAGG | 105          |
Table 3. Cont.

| Locus tag           | Protein description                  | Primer sequence (5′-3′)                                      | Size of PCR product (bp) |
|---------------------|--------------------------------------|------------------------------------------------------------|-------------------------|
| AFUA_2G11500(Erg28) | Ergosterol biosynthesis protein      | F: CTGCCCAAATGGCTCGTCT                                      | 104                     |
|                     | Erg28                                 | R: TGGAGGCTGTTGATTGCAGAG                                    |                         |
| AFUA_1G14550(MnSOD) | Mn superoxide dismutase               | F: CCTACGTCATGGCGCTGAATG                                    | 100                     |
|                     |                                      | R: GAAATTGATCGCTTGCTGCA                                    |                         |
| AFUA_6G07820(IMP)   | Integral membrane protein            | F: TGCATTACACCACATTGGCCA                                    | 105                     |
|                     |                                      | R: CAGAGCCCAAAATGATAGCCCA                                   |                         |
| AFUA_5G01030(GAPDH) | Glyceraldehyde3-phosphate dehydrogenase | F: TCGCTGAATGCCAATTTCTG                                     | 106                     |
|                     |                                      | R: AGCATCGACACTGGCGATATG                                    |                         |

3.7. Statistical Analysis

Statistical analysis was performed with SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). For all results analyses, Student’s *t* test was used. *P* < 0.05 was considered statistically significant.

4. Conclusions

In conclusion, our study shows that while BER is effective in restraining the growth of several different *A. fumigatus* strains, it is not synergistic with ICZ against *A. fumigatus* isolated from clinical patients. Therefore, it is not advised that BER and ICZ be used at the same time in the clinic. This observation is the first report showing evidence of mutual antagonism between BER and ICZ. BER significantly inhibits gene expression in the ergosterol biosynthesis pathway of *A. fumigatus* like ICZ.

Acknowledgments

This work was supported by the Department of Pathogenobiology, Norman Bethune College of Medicine, Jilin University; Jilin University Mycology Research Center (JUMRC), Changchun, China, and the Technical Center of Jilin Entry-Exit Inspection and Quarantine Bureau (JLCIQ) of P. R. China, and by grants from the National Natural Science Foundation of China (Project Code: No. 30770120, 30910103903). Thanka are due to Koji Yokoyama from the Medical Mycology Research Center, Chiba University, Japan for his help and guidance.

References and Notes

1. Gersuk, G.M.; Underhill, D.M.; Zhu, L.; Marr, K.A. Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. *J. Immunol.* 2006, 176, 3717-3724.
2. Gavalda, J.; Roman, A. Infection in lung transplantation. *Enferm. Infecc. Microbiol. Clin.* 2007, 25, 639-649; quiz 650.
3. Aydogan, S.; Kustimur, S.; Kalkanci, A. Comparison of glucan and galactomannan tests with real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model. *Mikrobiyol. Bul.* 2010, 44, 441-452.

4. Iwazaki, R.S.; Endo, E.H.; Ueda-Nakamura, T.; Nakamura, C.V.; Garcia, L.B.; Filho, B.P. *In vitro* antifungal activity of the berberine and its synergism with fluconazole. *Antonie Van Leeuwenhoek* 2009, 97, 201-205.

5. Limper, A.H.; Knox, K.S.; Sarosi, G.A.; Ampel, N.M.; Bennett, J.E.; Catanzaro, A.; Davies, S.F.; Dismukes, W.E.; Hage, C.A.; Marr, K.A.; *et al*. An official American thoracic society statement: Treatment of fungal infections in adult pulmonary and critical care patients. *Am. J. Respir. Crit. Care. Med.* 2011, 183, 96-128.

6. Billaud, E.M.; Guillemain, R.; Berge, M.; Amrein, C.; Lefeuvre, S.; Louet, A.L.; Boussaud, V.; Chevalier, P. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. *Med. Mycol.* 2010, 48 (Suppl. 1), S52-S59.

7. Kulkarni, S.K.; Dhir, A. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. *Phytother. Res.* 2009, 24, 317-324.

8. Cordero, C.P.; Gomez-Gonzalez, S.; Leon-Acosta, C.J.; Morantes-Medina, S.J.; Aristizabal, F.A. Cytotoxic activity of five compounds isolated from Colombian plants. *Fitoterapia* 2004, 75, 225-227.

9. Hawrelak, J. Giardiasis: Pathophysiology and management. *Altern. Med. Rev.* 2003, 8, 129-142.

10. Cecil, C.E.; Davis, J.M.; Cech, N.B.; Laster, S.M. Inhibition of H1N1 influenza A virus growth and induction of inflammatory mediators by the isoquinoline alkaloid berberine and extracts of goldenseal (*Hydrastis canadensis*). *Int. Immunopharmacol.* 2011, [Epub ahead of print].

11. Kim, J.H.; Campbell, B.C.; Mahoney, N.; Chan, K.L.; Molyneux, R.J.; May, G.S. Enhanced activity of strobilurin and fludioxonil by using berberine and phenolic compounds to target fungal antioxidative stress response. *Lett. Appl. Microbiol.* 2007, 45, 134-141.

12. Park, K.D.; Cho, S.J.; Moon, J.S.; Kim, S.U. Synthesis and antifungal activity of a novel series of 13-(4-isopropylbenzyl)berberine derivatives. *Bioorg. Med. Chem. Lett.* 2010, 20, 6551-6554.

13. Park, K.D.; Lee, J.H.; Kim, S.H.; Kang, T.H.; Moon, J.S.; Kim, S.U. Synthesis of 13-(substituted benzyl) berberine and berberrubine derivatives as antifungal agents. *Bioorg. Med. Chem. Lett.* 2006, 16, 3913-3916.

14. Xu, Y.; Wang, Y.; Yan, L.; Liang, R.M.; Dai, B.D.; Tang, R.J.; Gao, P.H.; Jiang, Y.Y. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: Endogenous ROS augmentation. *J. Proteome Res.* 2009, 8, 5296-5304.

15. Freile, M.L.; Giannini, F.; Pucci, G.; Sturniolo, A.; Rodero, L.; Pucci, O.; Balzareti, V.; Enriz, R.D. Antimicrobial activity of aqueous extracts and of berberine isolated from Berberis heterophylla. *Fitoterapia* 2003, 74, 702-705.

16. Nakamoto, K.; Tamamoto, M.; Hamada, T. *In vitro* study on the effects of trial denture cleansers with berberine hydrochloride. *J. Prostheth. Dent.* 1995, 73, 530-533.

17. Soffar, S.A.; Metwali, D.M.; Abdel-Aziz, S.S.; El-Wakil, H.S.; Saad, G.A. Evaluation of the effect of a plant alkaloid (berberine derived from *Berberis aristata*) on *Trichomonas vaginalis* in *vitro*. *J. Egypt Soc. Parasitol.* 2001, 31, 893-904 + 1p plate.
18. Sun, D.; Courtney, H.S.; Beachey, E.H. Berberine sulfate blocks adherence of *Streptococcus pyogenes* to epithelial cells, fibronectin, and hexadecane. *Antimicrob. Agents Chemother.* 1988, 32, 1370-1374.

19. Bian, X.; He, L.; Yang, G. Synthesis and antihyperglycemic evaluation of various protoberberine derivatives. *Bioorg. Med. Chem. Lett.* 2006, 16, 1380-1383.

20. Park, K.S.; Kang, K.C.; Kim, K.Y.; Jeong, P.Y.; Kim, J.H.; Adams, D.J.; Paik, Y.K. HWY-289, a novel semi-synthetic protoberberine derivative with multiple target sites in *Candida albicans*. *J. Antimicrob. Chemother.* 2001, 47, 513-519.

21. Park, K.S.; Kang, K.C.; Kim, J.H.; Adams, D.J.; Johng, T.N.; Paik, Y.K. Differential inhibitory effects of protoberberines on sterol and chitin biosyntheses in *Candida albicans*. *J. Antimicrob. Chemother.* 1999, 43, 667-674.

22. Xu, M.G.; Wang, J.M.; Chen, L.; Wang, Y.; Yang, Z.; Tao, J. Berberine-induced upregulation of circulating endothelial progenitor cells is related to nitric oxide production in healthy subjects. *Cardiology* 2009, 112, 279-286.

23. Liu, Z.; Liu, Q.; Xu, B.; Wu, J.; Guo, C.; Zhu, F.; Yang, Q.; Gao, G.; Gong, Y.; Shao, C. Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. *Mutat. Res.* 2009, 662, 75-83.

24. Holy, E.W.; Akhmedov, A.; Luscher, T.F.; Tanner, F.C. Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. *J. Mol. Cell. Cardiol.* 2009, 46, 234-240.

25. Zhang, W.; Xu, Y.C.; Guo, F.J.; Meng, Y.; Li, M.L. Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. *Chin. Med. J. (Engl.)* 2008, 121, 2124-2128.

26. Wang, Y.; Campbell, T.; Perry, B.; Beaurepaire, C.; Qin, L. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. *Metabolism* 2010, 60, 298-305.

27. Wang, Z.S.; Lu, F.E.; Xu, L.J.; Dong, H. Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells. *Acta Pharmacol. Sin.* 2010, 31, 578-584.

28. Wu, N.; Sarna, L.K.; Siow, Y.L.; Karmin, O. Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2010, 300, R635-R643.

29. Quan, H.; Cao, Y.Y.; Xu, Z.; Zhao, J.X.; Gao, P.H.; Qin, X.F.; Jiang, Y.Y. Potent *in vitro* synergism of fluconazole and berberine chloride against clinical isolates of *Candida albicans* resistant to fluconazole. *Antimicrob. Agents Chemother.* 2006, 50, 1096-1099.

30. Han, Y.; Lee, J.H. Berberine synergy with amphotericin B against disseminated candidiasis in mice. *Biol. Pharm. Bull.* 2005, 28, 541-544.

31. Klepser, M.E. New insights in medical mycology: Focus on fungal infections. Introduction. *Pharmacotherapy* 2001, 21, 109S-110S.

32. Carroll, P.M.; Dougherty, B.; Ross-Macdonald, P.; Browman, K.; FitzGerald, K. Model systems in drug discovery: Chemical genetics meets genomics. *Pharmacol. Ther.* 2003, 99, 183-220.

33. Bien, C.M.; Chang, Y.C.; Nes, W.D.; Kwon-Chung, K.J.; Espenshade, P.J. Cryptococcus neoformans site-2 protease is required for virulence and survival in the presence of azole drugs. *Mol. Microbiol.* 2009, 74, 672-690.
34. Ouyang, H.M.; Luo, Y.M.; Zhang, L.; Li, Y.J.; Jin, C. Proteome analysis of Aspergillus fumigatus total membrane proteins identifies proteins associated with the glycoconjugates and cell wall biosynthesis using 2D LC-MS/MS. Mol. Biotechnol. 2010, 44, 177-189.

35. Cornell, M.J.; Alam, I.; Soanes, D.M.; Wong, H.M.; Hedeler, C.; Paton, N.W.; Rattray, M.; Hubbard, S.J.; Talbot, N.J.; Oliver, S.G. Comparative genome analysis across a kingdom of eukaryotic organisms: specialization and diversification in the fungi. Genome Res. 2007, 17, 1809-1822.

36. Wang, L.; Yokoyama, K.; Miyaji, M.; Nishimura, K. The identification and phylogenetic relationship of pathogenic species of Aspergillus based on the mitochondrial cytochrome b gene. Med. Mycol. 1998, 36, 153-164.

37. Espinel-Ingroff, A.; Fothergill, A.; Fuller, J.; Johnson, E.; Pelaez, T.; Turnidge, J. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 2011, 55, 2855-2859.

38. Kim, J.H.; Campbell, B.C.; Mahoney, N.; Chan, K.L.; Molyneux, R.J.; May, G.S. Enhanced activity of strobilurin and fludioxonil by using berberine and phenolic compounds to target fungal antioxidative stress response. Lett. Appl. Microbiol. 2007, 45, 134-141.

39. Qiu, W.Y.; Yao, Y.F.; Zhu, Y.F.; Zhang, Y.M.; Zhou, P.; Jin, Y.Q.; Zhang, B. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis. Curr. Eye Res. 2005, 30, 1113-1120.

40. Rand, K.H.; Houck, H.J.; Brown, P.; Bennett, D. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob. Agents Chemother. 1993, 37, 613-615.

41. Odds, F.C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52, 1.

42. Alcazar-Fuoli, L.; Mellado, E.; Garcia-Effron, G.; Lopez, J.F.; Grimalt, J.O.; Cuenca-Estrella, J.M.; Rodriguez-Tudela, J.L. Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids 2008, 73, 339-347.

43. Nicot, N.; Hausman, J.F.; Hoffmann, L.; Evers, D. Housekeeping gene selection for real-time RT-PCR normalization in potato during biotic and abiotic stress. J. Exp. Bot. 2005, 56, 2907-2914.

44. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3, 1101-1108.

45. Tseng, C.P.; Cheng, A.J.; Chang, J.T.; Tseng, C.H.; Wang, H.M.; Liao, C.T.; Chen, I.H.; Tseng, K.C. Quantitative analysis of multidrug-resistance mdr1 gene expression in head and neck cancer by real-time RT-PCR. Jpn. J. Cancer Res. 2002, 93, 1230-1236.

46. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402-408.

Sample Availability: Samples of the compounds BER and ICZ are available from the authors.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).